Please login to the form below

Vernalis

This page shows the latest Vernalis news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA exec takes top job at UK biotech Kymab

He was also founder and CEO of Ribotargets, one of the UK’s earliest biotechs, which was acquired by British Biotech and subsequently renamed Vernalis.

Latest news

Boston Scientific makes $4.2bn play for UK’s BTG

The acquisition of BTG follows the buyout of another veteran of the UK biotech scene, Vernalis, which was acquired by Ligand Pharma in August for $33m, Vernalis's chequered history viewed
Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK. After mulling over several takeover offers, UK biotech Vernalis has been won over by an overture from California’s Ligand Pharma ... If Ligand’s offer is approved by Vernalis shareholders,
FDA knocks-back second Vernalis cough and cold treatment

Vernalis’ hopes of bringing either of its cough-cold drugs CCP-07 and CCP-08 to the US market in time for the 2017-2018 winter have been dashed. ... Ian Garland, chief executive officer of Vernalis, said: “Unfortunately, the outstanding items that
Juno cleared to restart CAR-T trial after deaths

Vipadenant was originally developed as a Parkinson's disease candidate by UK company Vernalis and licensed to Biogen, but its development was held back by safety concerns and Biogen eventually abandoned
Merck & Co drops Parkinson's prospect preladenant

2011. Meanwhile, Lundbeck was also working in this area with its Lu AA47070, but discontinued this project a couple of years ago, while Vernalis and Biogen Idec dropped their own candidate

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Medius Deal Watch table for February 2015

Corporate acquisition. 245††. Vernalis/ Not disclosed. Adenosine receptor antagonist programme, including the lead drug candidate, V81444.
Pharma deals in February 2015

Keeping the romance under wraps. It was announced in February that Vernalis has licensed its proprietary adenosine receptor antagonist programme, including the phase 1/2 lead compound V81444, for use in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Graham Belgrave joins Cmed Clinical Sciences

During his 30 year career in the pharmaceutical industry, Belgrave has held positions at GSK, Pfizer and Vernalis as well as working in consultancy and interim management positions, including for
Merck KGaA appoints biosimilar head

His prior experience in pharma includes several CEO positions, such as Vernalis, Lonza Biologics and Celltech Biologics.